CVS Health Updates Commercial Formularies, Reintroduces Zepbound

CVS Health announced updates to its most common commercial formularies, expanding GLP-1 options for members- including the reintroduction of Zepbound as a covered medication. Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members. The company said, "CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo, a new oral GLP-1 therapy, where approved for coverage by plans. Over the past year, we've been actively driving change in the GLP-1 weight management space to help lower costs. Our approach has made a real difference, enabling us to now expand options while continuing to make progress on affordability. We expect these changes to help drive increased savings in the weight management category - after a history of delivering double digit savings for our template formulary customers year over year - while expanding choice for our members."